Eli Lilly's Stock Awaits Pivotal FDA Verdict Amid Market Volatility

Eli Lilly shares fall despite blockbuster Q4 results. Investors await the April 2026 FDA ruling on oral obesity drug Orforglipron, a potential game-changer.

Despite posting stellar quarterly results and generating billions from its weight-loss medications, Eli Lilly & Company is currently experiencing a period of stock market weakness. Investors are looking past the record-breaking figures presented at the recent annual meeting, focusing instead on a critical date: April 10, 2026. On that day, the U.S. Food and Drug Administration (FDA) is set to rule on a new drug that has the potential to reshape the obesity treatment landscape.

This recent share price decline presents a stark contrast to the company's operational performance. The stock closed at €784.60 last Friday, marking a weekly drop of 8.61 percent. Operationally, however, the pharmaceutical giant is firing on all cylinders. Its Q4 2025 revenue of $19.29 billion significantly surpassed market expectations. The powerhouse drugs Mounjaro and Zepbound alone contributed well over $11 billion combined. For the current fiscal year, management is targeting total revenue in the range of $80 to $83 billion.

Analyst Confidence Endures

Market experts remain optimistic about Eli Lilly's prospects, even as competitors including Roche, Merck, and AbbVie aggressively push into the obesity market and U.S. government pricing pressure has already triggered price reductions. In mid-March, Swiss banking giant UBS reaffirmed its "Buy" rating, attaching a price target of $1,250.

The broader analyst community also continues to recommend purchasing the shares, a stance supported by a deep and diversified research pipeline. This pipeline extends beyond next-generation weight-loss treatments like Retatrutide to include therapies for chronic inflammatory bowel diseases. This diversification strategy is viewed as a way to reduce the company's future reliance solely on the GLP-1 drug segment.

The Promise of an Oral Contender

The most significant near-term catalyst for the stock is the impending FDA decision on Orforglipron, a daily GLP-1 pill. The regulatory body recently extended its review period by approximately two weeks, setting the new deadline for April 10, 2026.

This oral candidate offers distinct practical advantages. Unlike an already-approved rival product from Novo Nordisk, taking Orforglipron does not require strict fasting protocols or specific drinking instructions. Furthermore, analysts note that the pill is cheaper to manufacture and simpler to store than injectable alternatives, which could translate into higher profit margins for Eli Lilly upon approval. Pricing for self-pay patients through the company's direct pharmacy platform has already been set, ranging from $149 to $399 per dose.

Shareholders face two major milestones in the coming weeks. Following the FDA's verdict on April 10, the company will provide its next comprehensive business update with the release of its first-quarter 2026 results on April 30. These two data points are expected to be decisive in determining whether the equity can resume its long-term upward trajectory.